Health secretary calls industry ‘shortsighted’ but there is danger in giving UK better terms than much of rich Europe

ABPI is warning that the core ambition of the government's new life sciences strategy will not be realised unless it makes a real commitment to invest more in new medicines.

Two new pharma companies - Keenova and Par Health - have now emerged from the merger of Mallinckrodt and Endo earlier this year